Intravenous Iron Drugs Market – By Drug Type (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer), Distribution Channel (Hospital, Retail, Online) – Global Forecast 2024 – 2032

Intravenous Iron Drugs Market Size

Intravenous Iron Drugs Market size was valued at around USD 1.7 billion in 2023 and is estimated to grow at 6.7% CAGR from 2024 to 2032. Intravenous (IV) iron drugs are pharmaceutical formulations of iron administered directly into the bloodstream through intravenous injection or infusion. These drugs are used to treat or prevent iron deficiency anemia, particularly in patients who cannot absorb oral iron supplements effectively or who have conditions that require rapid replenishment of iron stores.
 

The rising prevalence of chronic diseases such as chronic kidney disease (CKD), cancer, and inflammatory disorders are significant driving factors for the market. For instance, according to the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths worldwide. This underscores the critical need for effective treatment options, including intravenous iron therapies, to manage anemia associated with these conditions and improve patient outcomes.
 

Furthermore, increasing awareness of the timely diagnosis of iron deficiencies, a growing geriatric population, and advancements in IV iron drug formulations are also contributing to revenue growth in the market.
 

Intravenous Iron Drugs Market Trends

Advancements in intravenous (IV) iron drug formulations have significantly transformed the landscape of iron deficiency treatment. Recent innovations focus on enhancing the safety, efficacy, and convenience of these therapies.
 

• Modern formulations, such as ferric carboxymaltose and ferric derisomaltose, are designed to allow for less frequent dosing compared to conventional IV iron products. These newer formulations have a longer half-life, meaning they remain in the body longer and maintain higher levels of iron in the bloodstream, reducing the need for repeated infusions.
   
• For instance, a study published in The New England Journal of Medicine in 2023 demonstrated that ferric carboxymaltose therapy effectively alleviates symptoms and enhances the quality of life for patients with heart failure and iron deficiency. This finding underscores ferric carboxymaltose's value in addressing iron deficiency within this patient population, potentially driving its adoption and market growth.
   
• New formulations also focus on minimizing adverse reactions, including allergies and anaphylaxis. Recent IV iron products are engineered to lower the chances of hypersensitivity reactions, thereby enhancing overall safety.
   
• Furthermore, innovations in novel drug delivery systems, such as nanoparticle-based formulations and liposome-encapsulated iron, are advancing intravenous iron therapies by improving stability, targeting, and controlled release. These technologies enhance bioavailability, extend infusion intervals, and minimize side effects, driving significant growth in the market.
   

Intravenous Iron Drugs Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on drug type, the market is segmented into iron dextran, iron sucrose, ferric carboxymaltose, and other drug types. The ferric carboxymaltose segment of the market is forecasted to reach USD 1.5 billion by 2032.
 

• Ferric carboxymaltose contains a high concentration of elemental iron per dose, allowing for effective treatment with smaller volumes compared to some other IV iron formulations. This can lead to fewer infusions and improved patient convenience.
   
• Ferric carboxymaltose can be administered quickly, with a typical infusion time of around 15 minutes. This is beneficial for patients who require prompt iron replenishment and for healthcare providers seeking to streamline treatment processes.
   
• Moreover, ferric carboxymaltose has a favorable safety profile. It is well-tolerated by patients and presents a reduced risk of severe allergic reactions compared to certain other IV iron formulations. These characteristic positions ferric carboxymaltose as an ideal choice for individuals with prior hypersensitivity reactions, subsequently driving growth in the market.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the intravenous iron drugs market is segmented into chronic kidney disease, inflammatory bowel disease, cancer, and other applications. The chronic kidney disease segment accounted for USD 1 billion in 2023.
 

• Patients with chronic kidney disease (CKD) often have impaired gastrointestinal absorption of iron, making oral iron supplements less effective. IV iron bypasses the digestive tract, providing a more direct and efficient way to replenish iron levels.
   
• Due to decreased erythropoietin production and ongoing inflammation, CKD often results in anemia. IV iron not only boosts hemoglobin levels but also enhances red blood cell production, playing a vital role in addressing anemia in CKD patients.
   
• IV iron provides rapid correction of iron deficiency, which is crucial for CKD patients needing immediate relief from anemia symptoms. Additionally, IV iron drugs are more tolerable than oral iron supplements, reducing the risk of gastrointestinal side effects. This combination of benefits drives revenue growth in the chronic kidney disease segment.
   

Based on distribution channel, the intravenous iron drugs market is bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is forecasted to reach USD 1.4 billion by 2032.
 

• Hospital pharmacies have specialized knowledge and expertise in managing IV iron therapies. Pharmacists can ensure the correct formulation, dosage, and administration schedule are chosen based on individual patient needs, minimizing the risk of errors and optimizing therapeutic outcomes.
   
• Hospital pharmacies are equipped to closely monitor patients receiving IV iron drugs for any adverse reactions or side effects. They can make necessary adjustments to the treatment regimen based on patient response, laboratory results, and clinical status, ensuring safe and effective therapy.
   
• Additionally, hospital pharmacies implement stringent quality control measures and aseptic techniques when preparing IV iron drugs. This careful methodology not only reduces the risk of contamination but also ensures the drugs' stability and efficacy, thereby driving market growth.
   

Looking for region specific data?

Download Free PDF

The growth of the intravenous iron drugs market in the U.S. is projected to reach USD 1 billion by 2032.
 

• The U.S. has a well-developed healthcare infrastructure, including state-of-the-art hospitals and specialized clinics. This infrastructure supports the effective administration and management of IV iron therapies, ensuring high-quality care for patients.
   
• The increasing prevalence of cancer in the U.S. is driving substantial growth in the market. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2020, there were 1,603,844 new cases of cancer reported, with 602,347 individuals losing their lives. The rising incidence of cancer is leading to a growing demand for IV iron therapies among patients with cancer-induced anemia.
   

The intravenous iron drugs market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK benefits from a well-established National Health Service (NHS) that provides comprehensive healthcare coverage and access to advanced treatments, including IV iron therapies. The NHS's structured system ensures that patients receive timely and effective treatment.
   
• Furthermore, increasing incidence of iron deficiency anemia in the UK is also contributing to an increasing demand for IV iron drugs. As reported by the National Institute for Health and Care Excellence (NICE), UK hospitals see approximately 57,000 emergency admissions each year attributed to iron deficiency anemia.
   

Japan intravenous iron drugs market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan is home to a robust pharmaceutical industry with significant expertise in drug development and manufacturing. Japanese companies are actively involved in the development of innovative IV iron formulations and delivery systems, driving market growth and advancements.
   
• The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan enforces rigorous regulatory standards for drug approval and safety. This stringent regulatory framework ensures that only high-quality and effective IV iron products are available in the market.
   

The market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The Saudi healthcare sector often collaborates with international pharmaceutical companies and research institutions. These partnerships facilitate the introduction of advanced IV iron products and treatment protocols.
   

Intravenous Iron Drugs Market Share

The market is highly competitive, with a mix of major global companies and smaller to medium-sized firms vying for market share. A key aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. These leading companies play a crucial role in shaping the market's trajectory. In addition to research and development efforts, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding the global footprint of prominent players. Meanwhile, smaller companies focus on specific drug types to compete with established vendors.
 

Intravenous Iron Drugs Market Companies

Some of the eminent market participants operating in the intravenous iron drugs industry include:

• AbbVie Inc.
• AdvaCare Pharma
• Akebia Therapeutics, Inc.
• AMAG Pharmaceuticals. Inc.
• Bayer AG
• Covis Pharma GmbH
• CSL Limited
• Daiichi Sankyo Company, Ltd.
• F. Hoffmann-La Roche Ltd.
• Fresenius SE & Co. KGaA
• Novartis AG
• PHARMACOSMOS A/S
• Rockwell Medical, Inc.
• Sanofi
• Zydus Lifesciences Limited       
                

Intravenous Iron Drugs Industry News:

• In March 2024, CSL Limited announced Health Canada's authorization of Ferinject (ferric carboxymaltose) for intravenous treatment of iron deficiency anemia in adults and pediatric patients aged one year and older, when oral iron is ineffective or not tolerated. This approval expands treatment options for patients facing challenges with oral iron therapy and underscores advancements in managing iron-related conditions.
   
• In June 2023, Daiichi Sankyo, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved INJECTAFER (ferric carboxymaltose injection) for treating iron deficiency in adult patients. This approval enabled Daiichi Sankyo to broaden the drug's use, potentially boosting its market share and revenue by addressing an unmet need in heart failure management and strengthening its position in the iron therapy market.
   

The intravenous iron drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Iron dextran
• Iron sucrose
• Ferric carboxymaltose
• Other drug types

Market, By Application

• Chronic kidney disease
• Inflammatory bowel disease
• Cancer
• Other applications

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa